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Abstract
Background: Cross-sectional serosurveys using IgG antibody to pertussis toxin (IgG-PT) are increasingly being used to
estimate trends in recent infection independent of reporting biases.
Methods/Principal Findings: We compared the age-specific seroprevalence of various levels of IgG-PT in cross-sectional
surveys using systematic collections of residual sera from Australian diagnostic laboratories in 1997/8, 2002 and 2007 with
reference to both changes in the pertussis vaccine schedule and the epidemic cycle, as measured by disease notifications. A
progressive decline in high-level ($62.5 EU/ml) IgG-PT prevalence from 19% (95% CI 16–22%) in 1997/98 to 12% (95% CI
11–14%) in 2002 and 5% (95% CI 4–6%) in 2007 was consistent with patterns of pertussis notifications in the year prior to
each collection. Concomitantly, the overall prevalence of undetectable (,5 EU/ml) levels increased from 17% (95% CI 14–
20%) in 1997/98 to 38% (95% CI 36–40%) in 2007 but among children aged 1–4 years, from 25% (95% CI 17–34%) in 1997/98
to 62% (95% CI 56–68%) in 2007. This change followed withdrawal of the 18-month booster dose in 2003 and preceded
record pertussis notifications from 2008 onwards.
Conclusions/Significance: Population seroprevalence of high levels of IgG-PT is accepted as a reliable indicator of pertussis
disease activity over time within and between countries with varying diagnostic practices, especially in unimmunised age
groups. Our novel findings suggest that increased prevalence of undetectable IgG-PT is an indicator of waning immunity
useful for population level monitoring following introduction of acellular vaccines and/or schedule changes.
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Introduction
Pertussis, also known as whooping cough, is a highly contagious
respiratory disease caused by infection with the bacterium
Bordetella pertussis. The most severe symptoms occur in childhood,
and infants too young to be vaccinated account for most deaths
[1]. In 2008, there were an estimated 16 million cases of pertussis
worldwide, resulting in the deaths of 195,000 children, mostly in
developing countries [2]. Many countries with well established,
high coverage vaccination programs are experiencing increasing
notifications, and a shift in disease burden from children to adults
[3].
Universal pertussis vaccination, using a combined diphtheria,
tetanus and whole cell pertussis vaccine (DTPw) commenced in
Australia in 1953 [4]. Since then, a number of changes have been
made to the timing of scheduled doses. Major schedule changes in
the last twenty years have been the addition of a pre-school
booster in 1994 to reduce levels of transmission in school aged
children [5], and the replacement of the 18 month booster with an
adolescent booster in 2003, to address increasing notifications in
adolescents [6]. Further, in the late 1990s, acellular vaccines
(DTPa) replaced the Australian-manufactured whole cell vaccine
[7]. Almost all acellular vaccines used in Australia have been
GlaxoSmithKline three component formulations, in various age
appropriate concentrations and combinations. The timeline of
changes, which have created many cohorts with different pertussis
vaccination experiences, is provided in Figure 1. Since 2003, the
Australian National Immunisation Program (NIP) pertussis
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with boosters at 4 years and 15–17 years, all with acellular
vaccines [7].
Vaccination coverage in Australia increased through the 1990s
and has been relatively stable at high levels since 2000. Reported
coverage in 2007 showed 92% of children nationally complete the
pertussis primary vaccination course by 12 months, rising to 95%
by two years of age [8]. Coverage estimates at the State level are
generally similar to National figures, although there is variation at
the finer geographic level of Australian Bureau of Statistics
statistical subdivision (SSD) [8]. In 2007, at least 85% of 12 month
old children in each SSD had completed the primary vaccination
course, with the exception of a small number of under-vaccinated
jurisdictions [8]. In 2007, around 89% of children received the
pertussis pre-school booster by six years of age [8].
In Australia, the use of pertussis notification rates to analyse
long term disease trends is confounded by changes in disease
awareness, increasing use of diagnostic testing and availability of
sensitive PCR diagnostic methods compared to earlier less
sensitive culture methods [9]. National notifications remained in
a relatively stable 3–4 year epidemic cycle from 1995 to 2005,
obscuring the underlying regional variability in cycle length
between states with different population densities [10]. From 2008
to 2011, however, both national and state notification rates
persisted at epidemic levels [11]. Although possibly influenced by
the increased use of PCR for diagnosis, the correlation with
hospitalisations indicates a genuine increase in the number of cases
[12]. Notably, increased notifications in children aged less than 10
years old were observed during the 2008–2011 epidemic, although
these ages were previously thought to be well protected by
vaccination.
Cross-sectional population serological surveys for pertussis
measure serum IgG antibodies to pertussis toxin (IgG-PT). An
IgG-PT level of 125 ELISA U/ml (EU/ml) or more is a highly
sensitive and specific marker of recent or active infection with B.
pertussis [13]. High sensitivity and specificity are major advantages
of serosurveillance over traditional forms of pertussis surveillance,
which are hampered by variable symptoms, diagnostic algorithms
and the dependence of diagnostic test sensitivity on age, previous
infections, vaccination status and time elapsed since the onset of
infection [1]. Serosurveillance can better estimate the population
level of infection as mild and asymptomatic cases can be detected,
allowing objective comparisons over time and between countries
using standardised assays.
This study analysed the cross-sectional population distribution
of IgG-PT levels during a period of low pertussis disease activity in
Australia and compared the results with two previous serosurveys
undertaken at different stages of the pertussis epidemic cycle. The
aim was to evaluate trends over time and explore links between
vaccination, the epidemic cycle and the cross-sectional serological
profile in age groups eligible and not eligible for routine
immunisation.
Methods
Ethics statement
Approval for the serosurvey was obtained from the Sydney West
Area Health Service Human Research Ethics Committee.
Informed consent was not obtained as the data were analysed
anonymously. In accordance with the provisions of the National
Health and Medical Research Council’s National Statement on
Ethical Conduct in Human Research, individual consent was not
required for use of these specimens, given the granting of
institutional approval by the Sydney West Area Health Service
Human Research Ethics Committee.
Study population and design
This study reports on findings from a serosurvey undertaken in
2007 for the purposes of evaluating immunity in Australia to a
range of vaccine preventable diseases, including pertussis. The
study design and laboratory methods are the same as those used
for the 1997/98 and 2002 serosurveys [4,7]. Briefly, the sera used
were randomly selected from a bank of approximately 7200 sera
collected under Australia’s national serosurveillance program.
These were residual samples from specimens submitted for
diagnostic testing to a nationally representative group of
laboratories and would otherwise have been discarded. Sera from
subjects who were immunosuppressed, had received multiple or
recent (within three months) blood transfusions, or were known to
be infected with HIV were excluded. Residual samples are often
used for pertussis serosurveillance [14–16], and this type of study
design has been shown to achieve similar results to population-
based cluster sampling for the measurement of immunity to
measles and mumps [17]. Sera were identified by sex, age, address
postcode (of the subject, if available, or the supplying laboratory)
and a unique identifier. Clinical information and pertussis
vaccination status were not collected.
Assay methods
A total of 3224 sera were randomly selected from the available
samples to fulfil calculated sample size requirements in each age
group, commencing at one year of age. Measurement of IgG-PT
levels was undertaken using an established ELISA method adapted
from Giammanco et al. [18] and described by Quinn et al. [7].
Figure 1. Timeline of major vaccination and reporting changes in Australia from 1953 to present. The timeline covers the
commencement of vaccination in 1953 through various schedule changes, the introduction of mandatory notification and changes to the vaccine
type used in Australia.
doi:10.1371/journal.pone.0035874.g001
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2007 studies, with the 1997/98 analysis conducted at the
European Sero-Epidemiology Network (ESEN) reference labora-
tory at the University of Palermo, Italy and the 2002 and 2007
analyses performed at the Centre for Infectious Diseases and
Microbiology (CIDM), Sydney, Australia. The method used at the
CIDM laboratory was validated against a panel of sera from the
ESEN reference laboratory.
The minimum level of detection of the assay was estimated to be
2 EU/ml. Antibody levels were divided into four categories,
suggestive of pertussis infection or vaccination, with immune
response, within the following time periods [15]: ,5 EU/ml
(undetectable), 5–,62.5 EU/ml (mid-range: more than one year
previously), 62.5–,125 EU/ml (high: within 12 months) and
$125 EU/ml (very high: within 6 months).
Pertussis surveillance data
In Australia, notification of both confirmed and probable
pertussis cases to the National Notifiable Diseases Surveillance
System (NNDSS) is mandatory [19]. According to the NNDSS
definition, confirmed cases require either laboratory definitive
evidence (‘‘isolation of Bordetella pertussis or detection of B. pertussis
by nucleic acid testing’’), or laboratory suggestive evidence
(‘‘seroconversion or significant increase in antibody level or
fourfold or greater rise in titre to B. pertussis in the absence of
recent pertussis vaccination; or single high IgA titre to whole cells;
or detection of B. pertussis antigen by immunofluorescence assay’’)
combined with clinical evidence (‘‘a coughing illness lasting two or
more weeks; or paroxysms of coughing or inspiratory whoop or
post-tussive vomiting’’), or clinical evidence combined with an
epidemiological link to a confirmed case [19]. Probable cases are
notified on the basis of clinical evidence only [19]; however the
strong reliance on direct notification from laboratories in Australia
and poor notification from clinicians [20] suggest that the great
majority of cases are now notified based on positive PCR or
serology. Annual pertussis notifications for the period 1991–2011
were obtained from published NNDSS data [11]. Incidence rates
per 100,000 population were calculated using these published
notification numbers, and Australian Bureau of Statistics mid year
population estimates [21].
Statistical methods
Age specific prevalence of IgG-PT levels in each category was
calculated, along with Clopper-Pearson confidence intervals.
Bonferroni corrections were applied to ensure a family confidence
level of 95% for comparisons across all years, equivalent to
individual confidence levels of 98.3%. Differences between groups
were considered statistically significant at the 5% level when these
confidence intervals did not overlap. Analysis was undertaken in
Microsoft Office Excel 2003 (Microsoft Corporation) and STATA,
version 11.2 (StataCorp).
Results
Epidemiologic context
Age specific notification rates per 100,000 population for 1991
to 2011 are shown in Figure 2, along with a trend line detailing the
percentage of cases in ages $15 years. Epidemics occur
approximately every three to four years against a background of
endemic disease. Serosurvey collections occurred at different
stages of the pertussis cycle: 1997/98 during and immediately
following an epidemic year; 2002 during a period of moderate
endemic activity; and 2007 at a trough in observed disease, prior
to a large epidemic sustained over the period 2008–2011. Yearly
notifications for the period 2008–2011 totalled 14292, 29799,
34793 and 38131 respectively.
Throughout the 1990s, the percentage of cases in ,15 year olds
gradually decreased, and from 1998–2011 most cases have
occurred in those aged $15 years and over. This reached a
maximum in 2006, when more than 90% of cases were notified in
the $15 years age group. During the 2008–2011 epidemic,
however, the percentage of notifications in these older ages
decreased. In particular, whilst only 15% of notifications occurred
in ,10 year olds for the period 1999–2004, this rose to over 30%
in 2011.
The highest notification rates during the 2008–2011 epidemic
occurred in the 0–4, 5–9 and 10–14 years age groups. In 2011,
notification rates in these three age groups (324, 385 and 544 cases
per 100,000 population respectively) were more than double those
in 1997, their maximums before this epidemic. Notification rates
in the 35–59 and $60 years age groups also rose sharply in 2008
and by 2010 the rates in these age groups (140 and 128 cases per
Figure 2. Age specific pertussis notification rates per 100,000 population for the period 1991 to 2011. In addition to the age specific
notification rates per 100,000 population, this graph includes a trend line showing the percentage of notifications occurring in over 15 year olds over
the same period.
doi:10.1371/journal.pone.0035874.g002
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maximums. The lowest rates during the 2008–2011 epidemic were
experienced by the 15–19 and 20–34 years age groups.
Overall trends in the population distribution of IgG-PT
levels
The cross-sectional distributions of IgG-PT levels by age (1–4
years) and age group ($5 years) for each of the three serosurveys
are shown in Figure 3. Age specific prevalence and Clopper-
Pearson confidence intervals are included for the undetectable (,5
EU/ml) and high-level ($62.5 EU/ml) categories in Table 1. In
this table and subsequent discussion the term ‘high-level’, referring
to antibody levels $62.5 EU/ml, includes those $125 EU/ml.
Across the three surveys, there were statistically significant
reductions in the population percentage with antibody levels
$62.5 EU/ml from 19% (95% CI 16–22%) in 1997/98 to 12%
(95% CI 11–14%) in 2002 and 5% (95% CI 4–6%) in 2007. Of
the 19% $62.5 EU/ml in 1997/98, 13% (95% CI 11–16%) were
$125 EU/ml.
The overall population percentage with undetectable antibodies
increased significantly from 17% (95% CI 14–20%) in 1997/98 to
37% (95% CI 35–40%) in 2002, remaining at 38% (95% CI 36–
40%) in 2007.
Trends in antibody distribution by age
Trends in antibody distributions by age category are described,
in groupings relevant to changes in the immunisation schedule
over the period (Figure 1).
High-level antibody prevalence in preschool children (1- to 4-
year-olds) declined markedly over the period. In infants aged from
1–2 years, this percentage fell from 17% (95% CI 6–35%) in 2002
to 1% (95% CI 0–7%) in 2007. Conversely, the percentage with
undetectable antibodies increased across this entire age band from
25% (95% CI 17–34%) in 1997/98 to 42% (95% CI 33–51%) in
2002 and significantly to 62% (95% CI 56–68%) in 2007.
The 5- to 9-year-olds had the largest percentage with high-level
antibody in 1997/98 with 30% (95% CI 23–37%). This
significantly reduced to 14% (95% CI 9–21%) in 2002, and to
4% (95% CI 2–7%) in 2007. Undetectable antibody prevalence
rose from 20% (95% CI 14–26%) in 1997/98 to 35% (95% CI
28–43%) in 2002 and 46% (95% CI 41–52%) in 2007.
Similar to observations in children aged ,10 years, a reduction
in the percentage of 10- to 19-year-olds with high-level antibody
was observed across the first two time points, associated with a
significant increase in the seronegative percentage. In contrast,
however, undetectable antibody prevalence for 15- to 19-year-olds
fell significantly between 2002 and 2007.
The percentage of adults ($20 years) with undetectable
antibodies increased across the surveys, from 10% (95% CI 5–
15%) in 1997/98 to 25% (95% CI 20–29%) in 2002 and 31%
(95% CI 28–34%) in 2007. High-level antibody prevalence
fluctuated from 10% (95% CI 5–15%) in 1997/98 to 16% (95%
CI 12–20%) in 2002 and 6% (95% CI 4–7%) in 2007.
Discussion
This study compared three pertussis serosurveys undertaken in
1997/98, 2002 and 2007, finding the cross-sectional population
distribution of IgG-PT levels in each survey was consistent with
the prevailing pertussis epidemic cycle and changes to the
nationally funded immunisation program. Whilst previous studies
have used high IgG-PT levels to indicate recent infection or
immunisation [4,7], one of the most notable observations of this
study was the temporal association between the high prevalence of
undetectable antibodies in 2007 and the large, sustained epidemic
which commenced in 2008. The significant increases in undetect-
able antibody prevalence between surveys suggest that waning of
antibody levels, including among adults, may occur rapidly during
periods of low B. pertussis circulation, when boosting opportunities
are reduced.
Pertussis notifications prior to and during the serum collection
provide the necessary epidemiologic context for interpretation of
each of the cross-sectional serosurveys. Although notification rates
include both confirmed and probable cases, we suspect that over
time the proportion of cases notified on the basis of clinical
evidence alone will have reduced, due to the increased testing
options available for different ages and stages of disease. The
1997/98 collection occurred during a major epidemic, likely
explaining the large population percentage with high-level
antibody. The 2002 collection followed several years of moderate
disease activity, consistent with the smaller number of individuals
with serologic evidence of recent infection [11]. A further
reduction in this number in 2007 is concordant with a relative
trough in reported cases in all age groups from 2005 to 2007 [22].
The extremely low prevalence of high and very high antibody
levels in the 2007 survey suggests vaccination has little impact on
the presence of high level antibody at the population scale,
supporting previous conclusions that high-level antibodies in 2002
were predominantly due to natural infection [7]. A pre-school
booster targeting 4- to 5-year-olds has been in place since 1994,
with an adolescent booster for 15- to 17-year-olds added to the
NIP in 2003. Consistent with this schedule, 4-year-olds and 15- to
19-year-olds had the largest percentages of high level antibody in
2007, however, this was only around 10%, despite high estimated
coverage of 89% for the 4-year-old booster [8], and moderate
estimated coverage in the range 55–76% for the adolescent
booster [6]. There was, however, a reduction in the percentage of
4-year-olds with undetectable antibodies compared with 3-year-
olds, and similarly 15- to 19-year-olds compared with 10- to 14-
year-olds in the 2007 survey. At the population level the
vaccination signature may be more apparent through a reduction
in the prevalence of undetectable antibody levels than an increase
in the prevalence of high levels.
One of the most notable findings of this study is the increase in
prevalence of undetectable antibodies in children aged from 1 to 3
years across the three collections, particularly between 2002 and
2007. High level antibodies in these ages are almost completely
absent in 2007, consistent with an increased time since last
vaccination compared with the same ages in 2002. These results
are compatible with rapid waning of antibodies following primary
vaccination with acellular vaccines [23,24] and the withdrawal of
the 18 month booster from the NIP in 2003. The temporal
association with the substantial increase in notification rates which
occurred in the 0–4 years age group from 2008 onwards suggests
that the absence of detectable antibodies may be an indicator of
increased susceptibility at the population level. An analysis of
notification rates in NSW for 2008 and 2009 showed that
incidence increases with age in 1–3 year olds and drops again in 4
year olds, when children receive the pre-school booster [12],
further supporting increased susceptibility due to waning antibody
levels.
Recent infection rates in 5- to 9-year-olds, approximated by the
prevalence of high-level antibodies, were sequentially lower across
the three serosurveys. This is consistent with the reducing rate of
notifications in these ages, from 216 per 100,000 in 1997, to 50.6
and 19.0 per 100,000 in 2001 and 2002 respectively, and to 9.9
and 13.5 per 100,000 in 2006 and 2007 respectively [11]. These
low infection rates, however, may have reduced opportunities for
Pertussis Antibody, Australia 1997–2007
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undetectable antibody levels seen in this age group. The low
notification rates observed from 2001 to 2007 have not been
sustained, with 115.8, 304.0, 421.1 and 544.7 cases per 100,000 in
2008 to 2011 respectively [11], again suggesting a possible link
between the high percentage with undetectable antibodies in 2007
and the magnitude and duration of the subsequent epidemic. It is
somewhat surprising that notification rates in this age group
reached such high levels from 2009–2011, given the inclusion of a
pre-school booster in the NIP since 1994. In 2007, the prevalence
of undetectable antibody levels increased with age from 37% in 5
year olds to 50% in 9 year olds (data not shown), suggesting
waning antibodies following the pre-school booster; notably most
of this age band would have also been eligible for an 18 month
booster. It is possible that the very high notification rates in this
age group in 2009–2011 were mainly due to infections in 8- and 9-
year olds, as occurred in previous epidemics [25]. This age cohort
would not have been eligible for an 18 month booster; differential
vaccine efficacy between epidemic and endemic circulation, as
previously found for whole cell vaccines [26], may also be a
contributory factor.
Mid-range antibody levels were predominant in the adult
population in 1997/98, when infection rates were high in the
under 20s and frequent natural boosting may have prevented
Figure 3. Cross-sectional distribution of anti-PT IgG levels. Distributions are shown by age (1–4 years) and age group ($5 years). A. 1997/98;
B. 2002; and C. 2007.
doi:10.1371/journal.pone.0035874.g003
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percentage with undetectable antibodies in adults has significantly
increased. Decreasing circulation in the higher coverage acellular
era may have reduced boosting opportunities, allowing waning of
antibodies to non protective levels [27] and potentially creating a
pool of highly susceptible adults of child bearing age. Booster doses
for parents and close contacts of newborns as part of a ‘cocooning’
strategy may improve immunity in this age group [10]. In the 2007
serosurvey, the 35–59 and $60 years age groups had high
prevalence of undetectable antibodies, and both of these age
groups experienced substantially increased notification rates in the
2008–2011 epidemic, similar to other age groups with high
prevalence of undetectable antibodies. It is interesting to note that
the 15–19 and 20–34 years age groups, which had the lowest
prevalence of undetectable antibodies in 2007, also experienced
the lowest notification rates in the 2008–2011 epidemic.
With potentially fewer biases than traditional forms of
surveillance, serosurveillance is increasingly being used to estimate
the incidence of pertussis infection by combining information on
antibody decay with seroprevalence data [16,28–31]. Using a cut-
off of 62.5 EU/ml to indicate infection within the previous 12
months, seroincidence in The Netherlands was estimated to be
approximately 9% [29], whilst the incidence of infection in Israel
was estimated at 2.4% [16]. Compared to the seroepidemiologic
profiles in Finland, France and Italy collected immediately
following an epidemic [15] and these results in The Netherlands
and Israel, our 1997/98 results show considerably higher levels of
infection. Using the same method, Australian seroincidence was
around 19% in 1997/98 for the overall population (and over 30%
for 5- to 9-year-olds), reducing to 12% in 2002 and 5% in 2007
(data not shown). Applying a method based on the entire antibody
distribution, Kretzschmar and colleagues estimated seroincidence
in five European countries ranged from 1% and 6% [30]. This
method requires an assumption that endemic equilibrium has been
reached, which would clearly be problematic in the Australian
setting given the variation in both numbers of disease reports and
seroprevalence of anti-PT antibodies observed in our survey.
Comparisons between consecutive Swedish serosurveys show
similarity to our results, despite a different vaccination schedule.
Overall antibody levels for both adults and children were lower in
2007 compared with 1997, ten years after the introduction of an
acellular pertussis vaccination program [32]. Hallander et al.
suggest that the combination of high prevalence of undetectable
antibodies and low frequency of infection may indicate reduced
herd immunity [24]. The distribution of IgG-PT antibodies in the
Australian population in 2007 relates closely to the Swedish
observations, and immediately preceded a sustained national
epidemic, supporting the notion of declining herd protection.
There were some limitations to this study. Firstly, the assays for
the 1997/98 survey were undertaken in a different laboratory to
those in 2002 and 2007. We believe, however, that potential biases
due to inter-laboratory differences were minimised through
validation of the method used in all surveys against the same
international standards and controls. Although the serosurveys of
2002 and 2007 showed mostly lower antibody levels than in 1997/
98, we do not attribute this to inter-laboratory differences, as the
levels were not consistently lower across all age groups.
Furthermore, the changes in results between surveys correlated
well with notification patterns which, although they may be
questionable in magnitude, nevertheless reflect overall infection
patterns quite well. Secondly, as the samples were drawn from
specimens submitted for diagnostic testing, the vaccination status
and health status of the subjects was unknown, and we cannot
exclude that the sample population was not a true reflection of the
general population and might have suffered from more disease.
Although some seroprevalence studies have used population-based
samples [29,32], many studies have used residual sera similar to
our study [14–16]. Convenience samples of residual sera from
diagnostic testing have been shown to achieve similar results to
population-based cluster sampling for the measurement of
immunity to measles and mumps [17], validating our use of this
method. Thirdly, unlike the Swedish study, we were not able to
exclude recently vaccinated individuals [32], although our results
suggest that the impact of this was minimal. There is no reason to
suspect that any biases differed substantially between the three
serosurvey collections.
To our knowledge, this study is the first to compare three
national serosurveys conducted at different points in the pertussis
epidemic cycle. Serosurvey data should be interpreted with
reference to the timing of serum collection in the prevailing
Table 1. Australian age specific population prevalence, expressed in percentages, for Undetectable (,5 EU/ml) and High ($62.5
EU/ml) antibody categories, with 95% Clopper-Pearson confidence intervals shown in brackets.
1997/98 2002 2007
Age group n ,5 EU/ml $62.5 EU/ml n ,5 EU/ml) $62.5 EU/ml n ,5 EU/ml) $62.5 EU/ml
1 39 23 (9–43) 10 (2–27) 42 29 (14–48) 17 (6–35) 97 63 (50–74){ 1 (0–7)
2 44 23 (10–41) 11 (3–28) 40 35 (18–55) 3 (0–16) 97 69 (57–80){ 1 (0–7)
3 37 27 (12–48) 11 (3–29) 41 59 (39–76) 2 (0–16) 100 70 (58–80) 1 (0–7)
4 43 26 (12–45) 14 (4–31) 42 45 (27–64) 14 (4–32) 99 47 (35–60) 8 (3–17)
1–4 163 25 (17–34) 12 (6–19) 165 42 (33–51) 9 (5–16) 393 62 (56–68){ 3 (1–5)
5–9 253 20 (14–26) 30 (23–37) 231 35 (28–43){ 14 (9–21)* 493 46 (41–52) 4 (2–7)*
10–14 314 17 (12–22) 18 (13–24) 742 45 (41–50){ 11 (8–14) 550 43 (38–48) 4 (2–6)*
15–19 109 13 (6–22) 22 (13–33) 306 39 (32–46){ 11 (7–16) 317 22 (17–29)* 10 (6–15)
20–34 77 10 (4–22) 14 (6–26) 365 24 (19–30) 15 (11–20) 987 26 (23–30) 7 (5–9)*
35–59 90 7 (2–16) 4 (1–13) 190 26 (19–34){ 18 (12–25) 235 45 (37–53){ 3 (1–7)*
60+ 48 15 (6–28) 13 (5–25) 249 37 (31–43){ 3 (1–6) *
*significantly lower than previous collection.
{significantly higher than previous collection.
doi:10.1371/journal.pone.0035874.t001
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immunisation program and vaccine immunogenicity. Although
our data showed some evidence of vaccination, the vaccine signal
was very weak and the population distribution of IgG-PT levels
was dominated by natural infection and waning of antibodies in
the absence of exposure or vaccination. While no defined antibody
level has been identified as a single correlate of protection against
pertussis, low IgG-PT levels have been shown to correlate with
susceptibility to infection following household exposure [33].
Although our study design does not allow causal inferences to be
made, the temporal association between increased population
prevalence of undetectable antibodies and a large, sustained
epidemic warrants further investigation.
The increase in the seronegative proportion between surveys
supports studies which have shown antibodies wane relatively
quickly after infection and vaccination, raising the possibility of a
corresponding increase in the susceptible population. Further work
will use mathematical models of pertussis transmission to explore
the impact of vaccination changes on the population distribution
of IgG-PT levels and test whether IgG-PT levels correlate with
protection at the population level.
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